The Lots of News and State Taxes, Too Edition | Essential: The Pharmacy Compounding Podcast

This episode of Essential: The Pharmacy Compounding Podcast covers a mix of regulatory and business topics relevant to independent pharmacy compounders. The main segments address peptide compounding, animal-derived thyroid (ADT) products, documentation requirements, state regulation recommendations, and a substantial deep dive into tax issues specific to compounding pharmacies. The hosts reference several key resources: an APC (American Pharmacists Association or similar body) issue brief on peptide compounding, a detailed 83-page citizen petition to the FDA regarding ADT compounding, FDA's proposed GFI 256B guidance, NABP's model pharmacy act, and accounting services tailored to compounding pharmacies. The episode appears to blend news and analysis—covering recent developments in the compounding space—with practical business guidance. The tax segment is positioned as particularly valuable, described as addressing "unique tax issues compounders face" that can be "pretty darned daunting." The show notes suggest the episode delivers timely regulatory updates (FDA guidance, state regulation recommendations) alongside actionable business content. However, the show notes provide limited detail about specific guests, the depth of analysis on each topic, or concrete takeaways beyond the topics listed. The episode runs 33 minutes, which is a reasonable length for a news-focused show but suggests some topics may receive only brief treatment. The framing emphasizes both "interesting" and "important" news, suggesting editorial judgment about relevance. The inclusion of linked resources and a CPA firm specializing in compounding pharmacy services indicates the show aims to be practical and resource-oriented for its niche audience.

Verdict: A solid, timely resource for compounding pharmacists seeking regulatory updates and business guidance, but limited show notes prevent full assessment of depth and expert credibility.

News rubric

• Accuracy and sourcing 3/5 20%

  Episode links to primary sources (FDA guidance, citizen petition, NABP model act) suggesting sourcing, but show notes don't detail how claims are verified or expert credentials.

• Balance and context 3/5 20%

  Multiple topics covered (peptides, ADT, documentation, taxes, regulation) suggest breadth, but show notes don't indicate whether competing viewpoints or regulatory pushback are addressed.

• Timeliness and relevance 4/5 15%

  References recent FDA guidance (GFI 256B), current regulatory developments, and state regulation recommendations; clearly timely for the compounding pharmacy audience.

• Substance 3/5 15%

  Mix of news items and a dedicated tax deep dive suggests solid content, but 33 minutes across multiple topics may mean some receive only surface treatment.

• Delivers on its title 4/5 15%

  Title promises "lots of news and state taxes"—episode delivers news roundup and dedicated tax segment, matching the promise well.

• Value for time 3/5 15%

  33 minutes covering multiple topics plus a tax deep dive is reasonably paced, but breadth across news items may limit depth on any single issue.

How we score News

Worth it if you own or work in a compounding pharmacy and need to stay current on FDA guidance, state regulation, and tax planning specific to your business.

Based on the episode description. AI-generated; it can be wrong.